The abstract is read at the publisher; the summary is JClub's.
ACE-339, an orally bioavailable small molecule, disrupts insoluble TDP-43 aggregates by directly targeting TDP-43 hexamers and rescues TDP-43 gain- and loss-of-function phenotypes.
- Why it matters: ALS lacks a cure, and in sporadic ALS >97% of patients show cytoplasmic mislocalization and aggregation of nuclear TDP-43 plus reduced nuclear TDP-43 that impairs mRNA binding and splicing.
- What they did: Using a machine learning platform, the study identified ACE-339 and tested it across in vitro, in vivo, and in silico models, including direct binding to aggregated TDP-43 and disaggregation of recombinant TDP-43.
- The result: ACE-339 rescues TDP-43–dependent mis-splicing and synaptic activity and improves disease-associated phenotypes in two independent mouse models, supporting further development toward clinical trials.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.